Aura Biosciences: A Pivotal Trial Engineered With Room To Spare (NASDAQ:AURA)
· seekingalpha.com
Aura Biosciences offers a fully funded ocular oncology play with a Phase 3 upside and limited financing risk. Click to read more on AURA here.
Aura Biosciences’ ( AURA ) upside doesn’t rely mostly on the great headline numbers in Phase 2 for bel-sar—although those numbers are solid. Instead, my b...